Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Nov. 7, 2013—Recent advances in robotics technology make it possible to create prosthetics that can duplicate the natural movement of human legs which promises to dramatically improve the mobility of lower-limb amputees.
Oct. 11, 2012—Vanderbilt is taking part in a national study to test in older adults the use of a vaccine designed to protect children against a common cause of pneumonia.
Jul. 24, 2012—Creating a device out of human cells that simulates brain chemistry is the goal of a $6.4 million grant which is part of major new federal initiative to develop a series of “organs on a chip” designed to improve the drug development process.
Nov. 2, 2011—Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.